Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704488 | 0.89 | ALDH1A1 (0.46) | BCHEACHEMAPK10BAZ2BCYP1A1 | |
| SCHEMBL4703977 | 0.88 | CYP1A2 (0.46) | BCHEACHEBAZ2BCYP1A1CYP1A2 | |
| SCHEMBL4702154 | 0.88 | CYP1A1 (0.46) | BCHEACHEMAPK10BAZ2BCYP1A1 | |
| SCHEMBL4699148 | 0.86 | BCHE (0.53) | BCHEACHECYP1A1CYP1A2CYP1B1 | |
| SCHEMBL4701421 | 0.86 | CYP1A2 (0.54) | BCHEACHEMAPK10RIPK1BAZ2B | |
| SCHEMBL4699107 | 0.81 | CYP1A2 (0.46) | BCHEACHEMAPK10RIPK1CYP1A1 | |
| SCHEMBL5943555 | 0.81 | ALDH1A1 (0.50) | BCHEACHEMAPK10BAZ2BCYP1A1 | |
| SCHEMBL14425117 | 0.79 | CYP1A1 (0.49) | BCHEACHEMAPK10BAZ2BCYP1A1 | |
| SCHEMBL4699549 | 0.77 | KDM4E (0.35) | CYP1A2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL4704080 | 0.77 | CYP1A2 (0.58) | ACHEMAPK10RIPK1CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390367-B1 | DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE | MACEF (FR) | 2008-07-09 | — | — | EP | claimed |
| US-7291627-B2 | Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug | MACEF (FR) | 2007-11-06 | — | — | US | claimed |
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | MACEF (FR) | 2006-04-27 | — | — | US | claimed |
| EP-1390367-B1 | DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE | MACEF (FR) | 2008-07-09 | — | — | EP | disclosed |
| US-7291627-B2 | Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug | MACEF (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | MACEF (FR) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089372-A1 | Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine | GDI2, GDI1, CYP2A7 | BCHE 1627/4885ACHE 1647/4885MAPK10 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.